Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort

OBJECTIVES: Tocilizumab showed trends for improving skin fibrosis and prevented progression of lung fibrosis in systemic sclerosis (SSc) in randomised controlled clinical trials. We aimed to assess safety and effectiveness of tocilizumab in a real-life setting using the European Scleroderma Trial an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuster, Simon, Jordan, Suzana, Elhai, Muriel, Held, Ulrike, Steigmiller, Klaus, Bruni, Cosimo, Cacciapaglia, Fabio, Vettori, Serena, Siegert, Elise, Rednic, Simona, Codullo, Veronica, Airo, Paolo, Braun-Moscovici, Yolanda, Hunzelmann, Nicolas, Joao Salvador, Maria, Riccieri, Valeria, Gheorghiu, Ana-Maria, Alegre Sancho, Juan José, Romanowska-Prochnicka, Katarzyna, Castellví, Ivan, Kötter, Ina, Truchetet, Marie-Elise, López-Longo, FJ, Novikov, Pavel I, Giollo, Alessandro, Shirai, Yuichiro, Belloli, Laura, Zanatta, Elisabetta, Hachulla, Eric, Smith, Vanessa, Denton, Chris, Ionescu, Ruxandra M, Schmeiser, Tim, Distler, Joerg H W, Gabrielli, Armando, Hoffmann-Vold, Anna-Maria, Kuwana, Masataka, Allanore, Yannick, Distler, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639158/
https://www.ncbi.nlm.nih.gov/pubmed/36328401
http://dx.doi.org/10.1136/rmdopen-2022-002477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639158/
https://www.ncbi.nlm.nih.gov/pubmed/36328401
http://dx.doi.org/10.1136/rmdopen-2022-002477

Ejemplares similares